about
Parkinson's disease gene therapy: success by design meets failure by efficacyTargeting caspase-3 as dual therapeutic benefits by RNAi facilitating brain-targeted nanoparticles in a rat model of Parkinson's disease.Differentiated neuroprogenitor cells incubated with human or canine adenovirus, or lentiviral vectors have distinct transcriptome profiles.Gene therapy for misfolding protein diseases of the central nervous system.Regenerative medicine for Parkinson's disease.Viral vector-based tools advance knowledge of basal ganglia anatomy and physiology.Towards a Better Treatment Option for Parkinson's Disease: A Review of Adult Neurogenesis.Transfection of the glial cell line-derived neurotrophic factor gene promotes neuronal differentiation.
P2860
Q26851325-88FA8167-325D-4AC3-8C55-4D778FDC04F9Q34722724-627160CD-236B-4D7C-ACD8-B355EC94D88DQ34904038-AEC97532-0327-47A9-8990-26C648DE8B37Q36983203-CD36AF71-40B8-438E-8438-1EFA2F6147D6Q38369065-B3AF3063-7621-4C76-B4EF-4877D1DDB41CQ38737932-520D60D2-5287-41FE-AE54-8FCE99C96606Q38950746-57386F11-33D6-49CE-80A2-E3CCB22B1613Q38957847-A0358D79-5D87-4D73-91E6-2F94D7EEB021
P2860
description
article
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у 2012
@uk
name
Gene therapy for Parkinson's disease
@en
Gene therapy for Parkinson's disease
@nl
type
label
Gene therapy for Parkinson's disease
@en
Gene therapy for Parkinson's disease
@nl
prefLabel
Gene therapy for Parkinson's disease
@en
Gene therapy for Parkinson's disease
@nl
P2860
P356
P1433
P1476
Gene therapy for Parkinson's disease
@en
P2093
Michael R Douglas
Rachel Denyer
P2860
P304
P356
10.1155/2012/757305
P407
P577
2012-01-01T00:00:00Z